Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Author's Avatar
Jan 31, 2023

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration has approved the company’s fourth-generation rechargeable sacral neuromodulation system.